K
Kevin Lou
Researcher at University of California, San Francisco
Publications - 11
Citations - 4147
Kevin Lou is an academic researcher from University of California, San Francisco. The author has contributed to research in topics: Drug repositioning & Phosphorylation. The author has an hindex of 8, co-authored 11 publications receiving 2686 citations. Previous affiliations of Kevin Lou include Howard Hughes Medical Institute & University of Pennsylvania.
Papers
More filters
Journal ArticleDOI
A SARS-CoV-2 protein interaction map reveals targets for drug repurposing.
David E. Gordon,Gwendolyn M. Jang,Mehdi Bouhaddou,Jiewei Xu,Kirsten Obernier,Kris M. White,Matthew J. O’Meara,Veronica V. Rezelj,Jeffrey Z. Guo,Danielle L. Swaney,Tia A. Tummino,Ruth Hüttenhain,Robyn M. Kaake,Alicia L. Richards,Beril Tutuncuoglu,Helene Foussard,Jyoti Batra,Kelsey M. Haas,Maya Modak,Minkyu Kim,Paige Haas,Benjamin J. Polacco,Hannes Braberg,Jacqueline M. Fabius,Manon Eckhardt,Margaret Soucheray,Melanie J. Bennett,Merve Cakir,Michael McGregor,Qiongyu Li,Bjoern Meyer,Ferdinand Roesch,Thomas Vallet,Alice Mac Kain,Lisa Miorin,Elena Moreno,Zun Zar Chi Naing,Yuan Zhou,Shiming Peng,Ying Shi,Ziyang Zhang,Wenqi Shen,Ilsa T Kirby,James E. Melnyk,John S. Chorba,Kevin Lou,Shizhong Dai,Inigo Barrio-Hernandez,Danish Memon,Claudia Hernandez-Armenta,Jiankun Lyu,Christopher J.P. Mathy,Tina Perica,Kala Bharath Pilla,Sai J. Ganesan,Daniel J. Saltzberg,Rakesh Ramachandran,Xi Liu,Sara Brin Rosenthal,Lorenzo Calviello,Srivats Venkataramanan,Jose Liboy-Lugo,Yizhu Lin,Xi Ping Huang,Yongfeng Liu,Stephanie A. Wankowicz,Markus Bohn,Maliheh Safari,Fatima S. Ugur,Cassandra Koh,Nastaran Sadat Savar,Quang Dinh Tran,Djoshkun Shengjuler,Sabrina J. Fletcher,Michael C. O’Neal,Yiming Cai,Jason C.J. Chang,David J. Broadhurst,Saker Klippsten,Phillip P. Sharp,Nicole A. Wenzell,Duygu Kuzuoğlu-Öztürk,Hao-Yuan Wang,Raphael Trenker,Janet M. Young,Devin A. Cavero,Devin A. Cavero,Joseph Hiatt,Joseph Hiatt,Theodore L. Roth,Ujjwal Rathore,Ujjwal Rathore,Advait Subramanian,Julia Noack,Mathieu Hubert,Robert M. Stroud,Alan D. Frankel,Oren S. Rosenberg,Kliment A. Verba,David A. Agard,Melanie Ott,Michael Emerman,Natalia Jura,Mark von Zastrow,Eric Verdin,Eric Verdin,Alan Ashworth,Olivier Schwartz,Christophe d'Enfert,Shaeri Mukherjee,Matthew P. Jacobson,Harmit S. Malik,Danica Galonić Fujimori,Trey Ideker,Charles S. Craik,Stephen N. Floor,James S. Fraser,John D. Gross,Andrej Sali,Bryan L. Roth,Davide Ruggero,Jack Taunton,Tanja Kortemme,Pedro Beltrao,Marco Vignuzzi,Adolfo García-Sastre,Kevan M. Shokat,Brian K. Shoichet,Nevan J. Krogan +128 more
TL;DR: A human–SARS-CoV-2 protein interaction map highlights cellular processes that are hijacked by the virus and that can be targeted by existing drugs, including inhibitors of mRNA translation and predicted regulators of the sigma receptors.
Posted ContentDOI
A SARS-CoV-2-Human Protein-Protein Interaction Map Reveals Drug Targets and Potential Drug-Repurposing
David E. Gordon,Gwendolyn M. Jang,Mehdi Bouhaddou,Jiewei Xu,Kirsten Obernier,Jeffrey Z. Guo,Danielle L. Swaney,Tia A. Tummino,Tia A. Tummino,Ruth Hüttenhain,Robyn M. Kaake,Alicia L. Richards,Beril Tutuncuoglu,Helene Foussard,Jyoti Batra,Kelsey M. Haas,Maya Modak,Minkyu Kim,Paige Haas,Benjamin J. Polacco,Hannes Braberg,Jacqueline M. Fabius,Manon Eckhardt,Margaret Soucheray,Melanie J. Bennett,Merve Cakir,Michael McGregor,Qiongyu Li,Zun Zar Chi Naing,Yuan Zhou,Shiming Peng,Shiming Peng,Ilsa T Kirby,Ilsa T Kirby,James E. Melnyk,James E. Melnyk,John S. Chorba,John S. Chorba,Kevin Lou,Kevin Lou,Shizhong Dai,Shizhong Dai,Wenqi Shen,Wenqi Shen,Ying Shi,Ying Shi,Ziyang Zhang,Ziyang Zhang,Inigo Barrio-Hernandez,Danish Memon,Claudia Hernandez-Armenta,Christopher J.P. Mathy,Tina Perica,Tina Perica,Kala Bharath Pilla,Kala Bharath Pilla,Sai J. Ganesan,Sai J. Ganesan,Daniel J. Saltzberg,Daniel J. Saltzberg,Rakesh Ramachandran,Rakesh Ramachandran,Xi Liu,Xi Liu,Sara Brin Rosenthal,Lorenzo Calviello,Srivats Venkataramanan,Jose Liboy-Lugo,Yizhu Lin,Stephanie A. Wankowicz,Markus Bohn,Phillip P. Sharp,Raphael Trenker,Janet M. Young,Devin A. Cavero,Joseph Hiatt,Joseph Hiatt,Theodore L. Roth,Theodore L. Roth,Ujjwal Rathore,Advait Subramanian,Julia Noack,Mathieu Hubert,Ferdinand Roesch,Thomas Vallet,Bjoern Meyer,Kris M. White,Lisa Miorin,Oren S. Rosenberg,Kliment A. Verba,Kliment A. Verba,David A. Agard,Melanie Ott,Melanie Ott,Michael Emerman,Davide Ruggero,Davide Ruggero,Adolfo García-Sastre,Natalia Jura,Mark von Zastrow,Jack Taunton,Alan Ashworth,Olivier Schwartz,Marco Vignuzzi,Shaeri Mukherjee,Matthew P. Jacobson,Harmit S. Malik,Danica Galonić Fujimori,Danica Galonić Fujimori,Trey Ideker,Charles S. Craik,Stephen N. Floor,James S. Fraser,James S. Fraser,John D. Gross,John D. Gross,Andrej Sali,Tanja Kortemme,Pedro Beltrao,Kevan M. Shokat,Kevan M. Shokat,Brian K. Shoichet,Brian K. Shoichet,Nevan J. Krogan +123 more
TL;DR: The identification of host dependency factors mediating virus infection may provide key insights into effective molecular targets for developing broadly acting antiviral therapeutics against SARS-CoV-2 and other deadly coronavirus strains.
Journal ArticleDOI
KRAS G12C inhibition produces a driver-limited state revealing collateral dependencies
Kevin Lou,Veronica Steri,Alex Y. Ge,Y. Christina Hwang,Christopher Yogodzinski,Arielle Shkedi,Alex Choi,Dominique C. Mitchell,Danielle L. Swaney,Byron Hann,John D. Gordan,Kevan M. Shokat,Luke A. Gilbert +12 more
TL;DR: Using functional genomics that identified pathway rewiring in ARS-1620–treated lung and pancreatic cancer cells, the authors found combination therapies that either enhanced target engagement by ARS -1620 (namely, EGFR, FGFR, or SHP2 inhibitors) or suppressed persistent tumor cell survival pathways (Namely, AXL, PI3K, or CDK4/6 inhibitors).
Journal ArticleDOI
p27 allosterically activates cyclin-dependent kinase 4 and antagonizes palbociclib inhibition.
Keelan Z. Guiley,Keelan Z. Guiley,Jack W. Stevenson,Kevin Lou,Krister J. Barkovich,Vishnu Kumarasamy,Tilini U. Wijeratne,Katharine L. Bunch,Sarvind Tripathi,Erik S. Knudsen,Agnieszka K. Witkiewicz,Kevan M. Shokat,Seth M. Rubin +12 more
TL;DR: A crystal structure of the CDK4 holoenzyme reveals that p27 allosterically activatesCDK4 to phosphorylate Rb by remodeling the adenosine triphosphate–binding site and by promoting release of the kinase activation segment, and that tyrosine phosphorylation of p21 makes it a poor activator.
Journal ArticleDOI
Brain-Penetrant, Orally Bioavailable Microtubule-Stabilizing Small Molecules Are Potential Candidate Therapeutics for Alzheimer’s Disease and Related Tauopathies
Kevin Lou,Yuemang Yao,Adam T. Hoye,Michael J. James,Anne-Sophie Cornec,Edward G. Hyde,Virginia M.-Y. Lee,John Q. Trojanowski,Amos B. Smith,Kurt R. Brunden,Carlo Ballatore +10 more
TL;DR: Evaluated compounds from known classes of non-naturally occurring MT-stabilizing small molecules led to the identification of selected triazolopyrimidine and phenylpyrimidines that are orally bioavailable and brain-penetrant without disruption of Pgp function.